Amylyx Pharmaceuticals (Nasdaq: AMLX) reported positive topline results from its Phase 3 LUCIDITY clinical trial evaluating avexitide, an investigational GLP-1 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE